Injectable drugs, including monoclonal antibodies, are becoming crucial components in the management of chronic diseases. The most common side effects are local reactions at the site of administration. With the increased and prolonged use of these medications, we are seeing increased reports of hypersensitivity reactions. The aim of this article is to discuss the signs and symptoms of these reactions as well as management, which may involve desensitization for 3 commonly encountered injectable drugs: tumor necrosis factor-α inhibitors (etanercept and adalimumab), insulin, and omalizumab.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.iac.2017.06.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bioactive hydrogel formulations for regeneration of pathological bone defects.
J Control Release
January 2025
Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun 130022, China. Electronic address:
Bone defects caused by osteoporosis, infection, diabetes, post-tumor resection, and nonunion often cause severe pain and markedly increase morbidity and mortality, which remains a significant challenge for orthopedic surgeons. The precise local treatments to these pathological complications is essential to avoid poor or failed bone repair. Hydrogel formulations serve as injectable innovative platforms that overcome microenvironmental obstacles and as delivery systems for controlled release of various bioactive substances to bone defects in a targeted manner.
View Article and Find Full Text PDFNanoparticle encapsulation enables systemic IGF-Trap delivery to inhibit intra-cerebral glioma growth.
Neuro Oncol
January 2025
Department of Medicine, Division of Experimental Medicine, McGill University.
Background: Glioblastoma is an aggressive brain cancer with a 5-year survival rate of 5-10%. Current therapeutic options are limited, due in part to drug exclusion by the blood-brain barrier, restricting access of targeted drugs to the tumor. The receptor for the type 1 insulin-like growth factor (IGF-1R) was identified as a therapeutic target in glioblastoma.
View Article and Find Full Text PDFUndesignated Glucagon in Schools for the Treatment of Diabetes-Related Hypoglycemia: A 2025 Update.
NASN Sch Nurse
January 2025
Medical Writer/Sole Proprietor, K-File Medical Writing and Editing Services, LLC, Chicago, IL.
Hypoglycemia will occur on school grounds in students with diabetes who are receiving glucose-lowering drugs. Hypoglycemia may be severe, in which a student is unconscious or comatose. Fast-acting carbohydrates remain the first line of treatment for nonsevere hypoglycemia but preparedness with emergency injectable or intranasal glucagon is ideal.
View Article and Find Full Text PDFDeciphering the therapeutic effects of Xiyanping injection: insights into pulmonary and gut microbiome modulation, SerpinB2/PAI-2 targeting, and alleviation of influenza a virus-induced lung injury.
Virol J
January 2025
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, 100010, China.
Infection with Influenza A virus (IAV) induces severe inflammatory responses and lung injury, contributing significantly to mortality and morbidity rates. Alterations in the microbial composition of the lungs and intestinal tract resulting from infection could influence disease progression and treatment outcomes. Xiyanping (XYP) injection has demonstrated efficacy in clinical treatment across various viral infections.
View Article and Find Full Text PDFLipid-Lowering Efficiency and Safety of Alirocumab 300 mg Using a 2-mL Autoinjector Device in Real-World Practice: The MARS Study.
Drugs Real World Outcomes
January 2025
Department of Cardiology, Angiology and Intensive Care Medicine, German Heart Center of the Charité, Berlin, Germany.
Background: Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 used for the reduction of low-density lipoprotein cholesterol (LDL-C) in high-risk patients not reaching their LDL-C target. Recently, a 2-mL prefilled autoinjector has been developed to support the monthly 300-mg dosing regimen with a single-injection administration.
Methods And Objectives: Monthly application of 300 mg AlirRocumab (Praluent) using the 2-mL SYDNEY Device (MARS) is a non-interventional, open, prospective, multi-center cohort study conducted in Germany between 2021 and 2023 with an observational period of 12 weeks.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!